Yousuf Zafar, MD
MD, University of Toledo
Dr. Zafar is a gastrointestinal medical oncologist and Associate Professor of Medicine, Public Policy, and Population Health Science at the Duke Cancer Institute and Duke-Margolis Center for Health Policy. He serves as Chief Quality & Innovation Officer at the Duke Cancer Institute. Dr. Zafar also serves as Clinical Associate Director of Duke Forge (Health Data Science Center). He explores ways to improve cancer care delivery with a primary focus on improving quality and value of cancer treatment from both patient-focused and policy perspectives.
Dr. Zafar speaks internationally on his research and cancer care delivery. He has over 100 publications in peer-reviewed journals including the New England Journal of Medicine, the Journal of Clinical Oncology, and JAMA Oncology. His research has been funded by the National Institutes of Health and the American Cancer Society, among others. His work has been covered by national media outlets including New York Times, Forbes, Wall Street Journal, NPR, and Washington Post. He is a Fellow of the American Society of Clinical Oncology.
Strickler JH, Rushing CN, Uronis HE, Morse MA, Niedzwiecki D, Blobe GC, et al. Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. Oncologist. 2021 Jan 19;
Hussaini SMQ, Chino F, Rushing C, Samsa G, Altomare I, Nicolla J, et al. Does Cancer Treatment-Related Financial Distress Worsen Over Time? N C Med J. 2021 Jan;82(1):14–20.
Moss HA, Wu J, Kaplan SJ, Zafar SY. The Affordable Care Act's Medicaid Expansion and Impact Along the Cancer-Care Continuum: A Systematic Review. J Natl Cancer Inst. 2020 Aug 1;112(8):779–91.